Physician profile
Bernard C Spier
NPI 1871578468
$6,053.53
in general payments reported to CMS, 2019-2025
25 companies · $507 in 2025
The $507 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $670 · 2020: $1,292 · 2021: $676 · 2022: $808 · 2023: $1,179 · 2024: $922 · 2025: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,607.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $1,726.91 | 2019-2025 | Idosetr, Photrexa Cross-Linking Kit, Iaccess Precision Blade |
| Allergan, INC. | $1,255.78 | 2019-2022 | |
| Alcon Vision LLC | $716.24 | 2019-2025 | Clareon, Rocklatan, Eysuvis |
| Abbvie INC. | $498.54 | 2022-2025 | Durysta, Lumigan, Alphagan P |
| Johnson & Johnson Surgical Vision, INC. | $252.96 | 2019-2023 | Tecnis Simplicity, Tecnis Iol |
| Sight Sciences, INC. | $197.89 | 2020-2025 | Sion Surgical Instrument, Omni Surgical System |
| Biotissue Holdings INC. | $194.39 | 2022-2023 | |
| New World Medical,INC. | $169.84 | 2022 | |
| Bausch & Lomb Americas INC. | $153.73 | 2022-2025 | Vyzulta, Xiidra |
| Rxsight INC | $127.18 | 2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $119.42 | 2019 | |
| Oyster Point Pharma, INC. | $109.37 | 2022-2025 | Tyrvaya, Ryzumvi |
| Ivantis, INC | $92.43 | 2021 | |
| Novartis Pharmaceuticals Corporation | $84.50 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $77.52 | 2020-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $49.19 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $47.33 | 2019-2025 | |
| Dompe US, INC. | $37.88 | 2024-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $35.83 | 2024-2025 | Xdemvy |
| Shire North American Group INC | $29.42 | 2019 | |
| Merz North America, INC. | $18.70 | 2020 | |
| Rayner Intraocular Lenses Limited | $15.12 | 2022 | |
| Aerie Pharmaceuticals, INC. | $14.86 | 2021 | |
| Ocular Therapeutix, INC. | $14.33 | 2020 | |
| Genentech USA, INC. | $14.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernard Spier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.